Procaps Group S.A. (PROC)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
Corcept Therapeutics Incorporated's relacorilant met the primary endpoint in the phase 3 ROSELLA study for platinum-resistant ovarian cancer patients, boosting shares by over 90% the very same day. Upcoming catalysts include full trial data release at a medical conference, NDA filing in Q3 2025, and MAA submission to the EMA shortly afterward. Relacorilant also targets hypercortisolism with endogenous Cushing's Syndrome patients with an FDA PDUFA date set for December 30, 2025, based on positive GRACE, GRADIENT, and phase 2 study data.
Procaps Group S.A. (PROC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Procaps Group S.A. ever had a stock split?
Procaps Group S.A. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Melissa Angelini CEO | NASDAQ (NMS) Exchange | L7756P102 CUSIP |
| LU Country | 4,498 Employees | - Last Dividend | - Last Split | 30 Sep 2021 IPO Date |
Overview
Procaps Group S.A. is a global pharmaceutical company established in 1977 and headquartered in Luxembourg, Luxembourg. This organization is dedicated to the development, production, and marketing of pharmaceutical solutions across the world. Procaps Group serves a diverse range of healthcare needs through its comprehensive offerings, which include branded prescription drugs across multiple therapeutic areas, hospital drugs, over-the-counter (OTC) consumer healthcare products, and contract drug development and manufacturing services. Leveraging advanced soft gelatin capsule technologies amongst others, Procaps Group caters to a wide patient and consumer demographic, aiming to deliver innovative and effective healthcare solutions.
Products and Services
- Branded Prescription Drugs: These include medications in various therapeutic areas such as feminine care, pain relief, skin care, digestive health, cardiology, vision care, central nervous system, and respiratory health.
- Hospital Drugs: Catering to the needs of the healthcare institutions, the company offers a range of drugs for inpatient care including antibiotics, analgesics, blood clots, personal protective equipment, immunosuppressants, oncology, and more.
- Over-the-Counter Consumer Healthcare Products: Procaps Group provides a wide array of OTC products covering gastric intestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, supplements, and more. These products target approximately eight different therapeutic areas and aim to meet common health needs of consumers without the need for a prescription.
- Diabetes Solutions: Offering comprehensive care for diabetes, Procaps Group supplies blood glucose meters, telemonitoring for diabetes management, oral anti-diabetics, cosmeceuticals, insulin delivery systems, and more. These products aim at simplifying diabetes management for patients.
- Contract Drug Development and Manufacturing Services: The company extends its expertise to other pharmaceutical companies by providing contract services that specialize in drug development and manufacturing, especially focusing on soft gelatin capsule technologies. This service allows other companies to leverage Procaps Group’s manufacturing capabilities and expertise for their drug production needs.
